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Abstract
Background: Young men who have sex with men (YMSM) are disproportionately at risk for HIV and sexually transmitted
infections. Adapting and testing the effectiveness of the Young Men’s Health Project (YMHP), an efficacious intervention designed
to reduce substance use and condomless anal sex (CAS) among YMSM, at clinics in Miami, Detroit, and Philadelphia has the
potential to reduce HIV and STI disparities among urban YMSM.
Objective: This study (Adolescent Medicine Trials Network for HIV/AIDS Interventions [ATN] 145 YMHP) aims to adapt
YMHP for clinic and remote delivery by existing clinic staff and compare their effectiveness in real-world adolescent HIV clinics.
This protocol is part of the ATN Scale It Up program described in a recently published article by Naar et al.
Methods: This is a comparative effectiveness hybrid type-2 trial of the YMHP intervention with 2 delivery formats—clinic-based
versus remote delivery—offered following HIV counseling and testing. Phase 1 includes conducting focus groups with youth to
obtain implementation feedback about the delivery of the YMHP intervention and intervention components to ensure culturally
competent, feasible, and scalable implementation. Phase 2 includes recruitment and enrollment of 270 YMSM, aged 15 to 24
years, 90 at each of the 3 sites. Enrollment will be limited to HIV-negative YMSM who report recent substance use and either
CAS or a positive STI test result. Participants will be randomized to receive the YMHP intervention either in person or by remote
delivery. Both conditions involve completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis information
and navigation services. A minimum of 2 community health workers (CHWs) will be trained to deliver the intervention sessions
at each site. Sessions will be audio-recorded for Motivational Interviewing Treatment Integrity (MITI) fidelity coding, and CHWs
and supervisors will be given implementation support throughout the study period.
Results: Phase 1 focus groups were completed in July 2017 (n=25). Feedback from these focus groups at the 3 sites informed
adaptations to the YMHP intervention manual, implementation of the intervention, and recruitment plans for phase 2. Baseline
enrollment for phase 2 began in November 2018, and assessments will be at immediate posttest (IP)-, 3-, 6-, 9-, and 12-months
after the intervention. Upon collection of both baseline and follow-up data, we will compare the effectiveness and cost-effectiveness
of clinic-based versus remote delivery of YMHP in the context of health care access.
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Conclusions: We are conducting YMHP in 3 cities with high rates of YMSM at risk for HIV and STIs. When adapted for
real-world clinics, this study will help substance-using YMSM at risk for HIV and STIs and allow us to examine differences in
effectiveness and cost by the method of delivery.
Trial Registration: ClinicalTrials.gov NCT03488914; https://clinicaltrials.gov/ct2/show/NCT03488914 (Archived by WebCite
at http://www.webcitation.org/770WaWWfi)
International Registered Report Identifier (IRRID): DERR1-10.2196/11184
(JMIR Res Protoc 2019;8(5):e11184)   doi:10.2196/11184
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Introduction
Background
Young men who have sex with men (YMSM; aged 16-24 years)
are disproportionately at risk for HIV and sexually transmitted
infections (STIs). Although new HIV infections have fallen or
remained stable among other groups, YMSM have experienced
a 132% increase in new infections since 2002 [1]. From 2008
to 2011, YMSM aged 13 to 24 years had the greatest percentage
increase (22%) in new HIV infections [2]. YMSM of color are
especially at risk: in 2011, among YMSM aged 13 to 24 years
with HIV infection, 58% were black and 20% were Latino [2].
Young males aged 15 to 24 years are vastly overrepresented in
rates of STIs. In 2013, males aged 15 to 24 years accounted for
more than half (57%) of all male cases of Chlamydia trachomatis
(CT) infection and 46% of Neisseria gonorrhea (GC) [3]. Young
men aged 20 to 24 years had the highest rate of syphilis from
2008 to 2012 [3]. Furthermore, sexual orientation disparities
exist—for example, men who have sex with men (MSM)
accounted for 75% of all syphilis cases in 2013 [3]. Ethnic and
racial disparities exist in the incidence of other STIs among
YMSM [3]. Young black men aged 15 to 24 years have a rate
of CT infection 5.5-9.5 times higher and GC rates 10.4-13.0
times higher than white men [3]. A recent study of HIV-negative
MSM diagnosed with rectal CT or GC at STI clinics between
2008 and 2010 showed that such infections greatly increase
HIV incidence [4]. In 2013, MSM accounted for 3 quarters of
all primary and secondary syphilis cases diagnosed in the United
States—an increase of 10% since 2012 [3].
Location is also a risk factor. YMSM in large urban areas are
disproportionally affected. Detroit, Philadelphia, and Miami
have high rates of HIV and STIs among males. These cities are
geographically diverse and have large numbers of YMSM
receiving HIV counseling and testing annually by clinic sites
and community partners. This information points to the need
to study the effectiveness of the Young Men’s Health Project
(YMHP), for its significant public health potential in reducing
HIV/STI disparities among urban YMSM.
Evidence Base
Substance Use and HIV Risk Among Young Men Who
Have Sex With Men
MSM use substances at higher rates than the general population,
increasing HIV risk. High rates of drug and alcohol use among
MSM relative to the general population have been documented
[5-7], and our research has identified higher rates of drug use
among YMSM compared with heterosexuals [8-10]. Higher
rates of drug use have also been documented among MSM,
including YMSM in tandem with sexual activity [11,12].
However, drug-use patterns seem to differ among YMSM with
increased rates of cocaine among YMSM, which could have
implications for HIV risk given that stimulant use has been
linked to condomless anal sex (CAS) [13-16] and higher risk
of HIV infection and other STIs [17]. Nearly half of black MSM
with newly diagnosed HIV infection (48%) reported substance
use during their last anal sex encounter [11]. Substance use has
been found to increase sexual risk behavior among MSM [18],
placing them at high risk for CAS and HIV seroconversion,
exchange sex, and greater number of sexual partners [19]. Our
own research using event-level data for the previous 30 days
has shown that substance use strongly and significantly predicts
the odds of whether YMSM will use a condom [20]. A number
of other studies have looked at the impact of substance use on
sexual behavior and increased odds of seroconversion [11].
Different substances are associated with sexual risk behavior
among specific groups. Among Latino MSM, methamphetamine
use [21,22] and among black MSM higher rates of marijuana
use have been linked to sexual risk [23]. Therefore, there is a
critical need for brief, culturally appropriate, effective behavioral
interventions that improve self-management to reduce new HIV
infections among substance-using YMSM.
Effectiveness of Motivational Interviewing
Motivational interviewing (MI) has the potential to improve
self-management behaviors in terms of promoting sexual health
and reducing substance use among YMSM. There is strong
evidence that MI is a culturally appropriate and effective
approach for working with racial and ethnic minority populations
[24] who are disproportionately affected by HIV. One
meta-analysis of MI found a greater effect among minorities
[25]. MI has been recommended as particularly effective when
working with YMSM [26]. MI promotes increased intrinsic
motivation to change and, when paired with information
regarding health risk behaviors, reinforces the individuals’ right
and capacity to make well-informed health self-management
decisions for themselves [27].
YMHP, a manualized structured 4-session intervention using
MI and problem-solving skills building, has been listed as a
best evidence intervention by the Center for Disease Control
and Prevention (CDC) and is the only intervention to reduce
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both CAS and substance use among YMSM [28]. The CDC’s
endorsement of YMHP was informed by results of the National
Institutes of Health (NIH)-funded efficacy trial. A total of 143
HIV-negative YMSM (aged 18-29 years) who reported CAS
with a high-risk partner and at least 5 days of drug use in the
last 3 months were randomized to receive 4 sessions of YMHP
or 4 sessions of health education on sexual risk and substance
use. The majority [63%(90/145)] of the sample were YMSM
of color (black: 21%, Latino: 28.7%, or multiracial: 13.3%).
Retention rates were high: 79% at the 12-month follow-up and
88% completed at least 3 of the 4 sessions. Master’s level
therapists were trained in MI with ongoing fidelity monitoring
using the Motivational Interviewing Treatment Integrity (MITI)
coding system. YMSM who received YMHP reduced their
cross-time averaged odds of ever using any drug by 67% over
the 1-year follow-up. Within-condition analyses showed that
YMSM who received YMHP reduced their cross-time averaged
odds of ever having CAS by 83% over the 1-year follow-up.
YMSM in the YMHP condition were 21% less likely to report
CAS on days when they did report drug use relative to men
receiving education. This has been the first and only RCT with
HIV-negative YMSM to show significant reductions in both
CAS and substance use. As such, YMHP has the potential to
have a significant impact on YMSM seeking sexual health or
HIV counseling and testing services at clinics.
Remote Delivery
Research on telephone-based MI has consistently found that it
produces significant improvements in a wide range of physical
health challenges [29-31]. Furthermore, telephone-based MI
reduces mental health–related problems [32] and alcohol-related
problems [33] as well as sexual risk taking [31,34-36] among
HIV-positive individuals. Research comparing the effects of
telephone-based MI with face-to-face (clinic-delivered)
interventions has produced equivocal results. Across studies
examining physical activity, mental health, and substance use
outcomes, findings suggest no significant differences in delivery
method [34-37]. Carey et al examined the relative efficacy of
a telephone versus face-to-face intervention for alcohol use and
observed a significant interaction of delivery method with gender
[38]. Women on average had better outcome in the face-to-face
condition, whereas men responded equally well to both delivery
methods.
Notably, the issue of health care access has not yet been
examined as a moderator of relative effectiveness. One
advantage of telephone-based MI is that it significantly reduces
patient burden. It is, therefore, plausible that it will show
superior effects among YMSM who experience barriers to health
care access. However, it is also possible that remote delivery
(via phone or video chat using Skype or FaceTime) will decrease
engagement and the quality of the relationship between the
clinicians and the participant. This might result in clinic-based
delivery being superior among YMSM who have better access
to health care. Understanding how health care access intersects
with delivery method will substantially inform implementation
decisions at clinics and other agencies seeking to utilize YMHP.
Community Health Workers Intervention Delivery
Integrating implementation science into a comparative
effectiveness trial (CET) can minimize the science-practice gap
[39]. MI providers need not be clinicians—1 study conducted
by our team comparing community health workers (CHWs)
with clinicians found both were equally effective in providing
high-quality MI and that clients were more likely to be retained
in HIV care when working with CHWs [40]. CHWs are
commonly integrated into clinics and often play a central role
in providing HIV prevention services, including HIV counseling
and testing. Training CHWs to deliver evidence-based
interventions is a critical step toward realistic and cost-effective
implementation [41]. CDC has called for expanded use of CHWs
in services for chronic disease [42] with attention to
implementation and training [43-50].
Several steps can be taken in a CET of YMHP to promote
adoption and sustainability. First, using staff embedded in the
existing clinic setting can build capacity for implementation.
Second, CHWs have long been the cornerstone of integrating
support services into HIV-related prevention efforts [51].
Training CHWs to deliver interventions is a critical step toward
realistic and cost-effective implementation. Research has
documented the amount of training needed to obtain MI fidelity,
concluding that initial training followed by ongoing coaching
is required [52-55]. Such training can be costly when relying
on outside trainers. Thus, a train the trainer model where expert
trainers provide local supervisors with MI coaching skills might
be more sustainable [56]. Finally, CET designs help gain
information about implementation [57]. In a Hybrid 2 trial, the
goal is to dually determine which treatments work in which
settings and to simultaneously answer implementation science
questions about the potential barriers/facilitators to a treatment’s
widespread and continued implementation.
Aims
The aim of this paper is to describe Adolescent Medicine Trials
Network for HIV/AIDS Interventions (ATN) 145 YMHP to
study the scale-up of evidence-based practices in
multidisciplinary adolescent HIV care settings while balancing
flexibility and fidelity. The protocol is part of the Scale it Up
research program focusing on implementation of
self-management interventions to impact the adolescent HIV
prevention and care cascades [58]. The purpose of this study is
to adapt YMHP for clinic and remote delivery by existing HIV
clinic staff, CHWs, who work with YMSM aged 15 to 24 years.
This study also aims to (1) compare the effectiveness of
clinic-based versus remote delivery of YMHP in the context of
health care access by hypothesizing that remote-delivery will
yield significantly better results among youth who experience
barriers to health care access, whereas clinic-based delivery will
yield significantly better results among youth who do not, (2)
assess the cost-effectiveness of both formats of delivery to
increase the likelihood of uptake for this intervention, and (3)
assess the 5 components of the self-management model (ie,
problem solving, decision making, resource utilization, forming
of a patient and health care provider partnership, and taking
action) and how these components vary over time, are directly
improved by the interventions, and mediate intervention effects.
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Finally, a sustainable model of YMHP will be tested in
real-world adolescent clinics utilizing the Exploration,
Preparation, Implementation, Sustainment model (EPIS; see
ATN 153 EPIS protocol paper [59]).
Methods
Overview of Content and Delivery
This is a comparative effectiveness hybrid type-2 trial of the
YMHP intervention designed to achieve aims over 2 phases.
Phase 1 was completed by conducting focus groups with youth
as part of its formative research to obtain implementation
feedback about the delivery of the YMHP intervention and
intervention components to ensure culturally competent, feasible,
and scalable implementation both in the clinic setting and via
remote condition, when delivered by CHWs. For phase 2, the
target sample size is 270 YMSM, aged 15 to 24 years, 90 at
each of the 3 sites. Participants are randomized at the end of
their baseline assessment into 1 of the 2 intervention conditions:
(1) delivery of the YMHP intervention in person at the clinic
site or (2) delivery of the YMHP intervention by phone or video
chat using apps such as Skype or FaceTime. Everyone will
receive session 1 in person immediately upon completion of the
baseline assessment regardless of their randomization to the 2
intervention conditions. Those randomized to face-to-face
clinic-based delivery will schedule and complete their remaining
3 sessions in person, whereas those randomized to the remote
condition will schedule and complete the remaining 3 sessions
remotely.
The study will employ a stratified randomization procedure
based on city, minority status, and health care access, so that
within each city, youth who experience barriers to health care
access are distributed equally across conditions. We will also
stratify by interventionist and whether a youth has used
marijuana only versus other drugs in the past 3 months. Research
staff will complete a survey on Qualtrics that will randomize
participants into 1 of the 2 study groups with no masking to the
research staff or participant. Intervention sessions will occur
approximately once per week for 4 weeks beginning 1 week
after completion of the baseline assessment. There is a 12-week
window for intervention completion, that is, all 4 sessions must
be completed within 12 weeks of the baseline assessment. The
immediate posttest (IP) assessment will occur 3 months after
baseline and subsequent follow-ups will be scheduled 3 months
thereafter until the 12-month postintervention (ie, 15 months
postbaseline) assessment. Baseline, 3-month, and 9-month
assessments consist of self-report data collection (CASI) and
HIV and STI testing for CT, GC, and syphilis. The IP, 6-month,
and 12-month follow-up assessments require completing the
CASI only and can be completed remotely via email Qualtrics
link. All enrolled participants could receive up to US $275 by
the end of this study—US $50 for baseline, which includes
CASI, bio-testing, and session 1; US $30 for sessions 2 to 4;
US $20 as a bonus for completing all 4 sessions; US $25 for
CASI-only assessments (ie, for IP, 6-month, and 12-month
assessments); and US $50 for assessments with both CASI and
bio-testing (ie, for 3-month and 9-month assessments). The
participant flow diagram is presented in Figure 1.
Recruitment and Eligibility
Recruitment
The Center for HIV Educational Studies and Training (CHEST)
at Hunter College will use a variety of recruitment strategies to
recruit participants for this study. First, as a result of CHEST’s
role as the Management Core and Recruitment and Retention
Center (REC) for Scale It Up, we will utilize 3 Subject
Recruitment Venues (SRVs) in our network (Wayne State
University Prevention in Detroit, University of Miami, and
Children’s Hospital of Philadelphia) to complete clinic- and
field-based recruitment. All 3 SRVs, as well as CHEST, have
extensive relations with the gay, lesbian, bisexual, and
transgender communities; community service organizations;
health service organizations; and providers for MSM. In this
aspect, recruitment will occur from routine walk-in visits for
HIV testing. Partnering clinics will include offering this study
through outreach activities and through their HIV testing
services they provide in their clinics. Information about the
study will be included in the institutional review board
(IRB)-approved palm cards, brochures, and flyers at each clinic
site (see Figure 2). This information will be displayed in waiting
rooms and exam rooms at the clinic as well as at locations of
mobile testing events and outreach shifts to be passed to
potential participants to both encourage HIV testing and promote
the YMHP study. This method has worked well in the past for
numerous studies and takes advantage of when patients have
more idle time to learn about the study.
YMSM who test HIV negative at the 3 SRVs in Miami, Detroit,
and Philadelphia or through mobile testing efforts provided by
community collaborators will be offered the opportunity to
participate in YMHP. Those interested will be asked to complete
a brief Study Screener on a study iPad to collect demographic
and behavior questions related to eligibility criteria. Participant
ID numbers are generated and assigned through Qualtrics during
the screening process to all potential participants, including
those who screen ineligible. If eligible, a screen will be displayed
informing the potential participant of his eligibility, and the site
study staff person will then schedule the potential participant
for a baseline assessment. We anticipate enrollment of 5
participants per month, per SRV, and have allocated staffing
resources to ensure this rate.
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Figure 1. Participant flow diagram. YMHP: Young Men’s Health Project.
JMIR Res Protoc 2019 | vol. 8 | iss. 5 | e11184 | p.5https://www.researchprotocols.org/2019/5/e11184/
(page number not for citation purposes)
Parsons et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Figure 2. Young Men’s Health Project recruitment flyer.
In addition, CHEST will assist in referring potentially eligible
participants to the YMHP study through existing Web-based
recruitment efforts. CHEST utilizes the Hunter College
IRB-approved online master screener (OMS) used to
preliminarily screen individuals who are interested in
participating in studies being conducted through CHEST. If an
individual is preliminarily eligible for a study, the individual is
asked to provide contact information to CHEST for follow-up.
For the purposes of this study, the OMS will be used to refer
potentially eligible YMSM to HIV testing sites by sending them
an email referral informing them about the YMHP study and
where to go to determine eligibility after completing the OMS.
Potential participants will also be called by CHEST staff to
complete the Study Screener over the phone. If they meet the
study criterion, they will be scheduled by the study staff to
attend the clinic for HIV testing and YMHP enrollment. The
OMS, in this instance, will primarily be used as a referral
mechanism for the study, directing participants to which study
they might be eligible for, including YMHP.
Eligibility Criteria
All interested participants are assessed for eligibility by
completing a brief Study Screener. Study inclusion criteria
include (1) being aged between 15 and 24 years; (2) currently
identifying as male (regardless of birth sex); (3) receiving an
HIV-negative test result from a study site or mobile HIV testing
in the past 90 days; (4) having sex with men in the past 90 days;
(5) reporting at least 3 days of illicit drug use or heavy drinking
(5 or more drinks) in the past 90 days; (6) reporting at least one
episode of CAS with a male partner in the past 90 days or a
positive STI test result in the past 90 days; (7) living in the
Detroit, Miami, or Philadelphia metropolitan areas; and (8)
having the ability to communicate in English. Exclusionary
criteria include the following: (1) participants whose mental,
physical, or emotional capacity does not permit them to complete
the protocol as written; (2) currently taking Truvada as
pre-exposure prophylaxis (PrEP); and (3) 5 or more days of
injection drug use in the past 90 days.
Management and Tracking Study Visits
There are 2 different types of visits during the study timeline.
Research visits include all assessments including the baseline
visit, the posttest assessment, and all other follow-up
assessments. All participants, in either condition, are expected
to complete 6 research visits as part of full participation in the
study. Research visits will be tracked using REDCap, a secure
Web app for managing Web-based surveys and databases. This
system allows both SRV study staff and the REC staff to monitor
the completion of study visits and surveys and generate reports
on enrollment and retention as needed. SRV study staff will
track all completed study components in REDCap immediately
after completing an assessment no later than the end of the
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business day. Intervention visits include all YMHP sessions
between enrolled study participants and trained CHWs.
Intervention visits will be largely managed by the CHWs with
their individual study participants. CHWs will notify SRV study
staff of whether visits were completed for tracking purposes,
provide receipts for session compensation to SRV study staff,
and upload audio files to Dropbox Business as per study
procedures. CHWs will deliver the first YHMP session at the
completion of each baseline assessments immediately, regardless
of randomization, and will schedule the subsequent session in
person or remotely.
Intervention Design
YMHP has been listed as a best evidence intervention by the
CDC and is the only intervention to show significant effects on
both CAS and substance use among YMSM. MI techniques are
utilized to provide personalized feedback for reducing CAS and
substance use among YMSM. The YMHP intervention will be
delivered by MI-trained CHWs employed at SRVs, primarily
by former HIV counseling and testing counselors, health
educators, and trained program peers. Participants will be
randomized to receive the intervention either in person or
remotely by phone or via video chat using Skype or FaceTime.
Both conditions involve completion of the 4 YMHP sessions
and the delivery of PrEP information and navigation services
to interested participants.
Four Sessions of Young Men’s Health Project
In session 1, youth will choose which behavior to discuss first
(sexual risk or substance use), and the CHW will elicit the
participant’s view of the problem using standard MI techniques,
building motivation for change by eliciting and reinforcing
change talk and clarifying the youth’s own personal priorities
(through a structured card sorting activity). The CHW will assess
and reflect the participant’s readiness to make changes in target
behavior. If the participant is willing to proceed, goals on healthy
behaviors (ie, substance moderation, sex risk harm reduction
strategies) are set. The session ends with MI strategies to evoke
the youth’s ideas about how to take steps toward change,
consolidate the youth’s commitment to the plan, and problem
solving. Session 2 follows the same format as session 1 but
revolves around the second target behavior. Session 3 includes
a discussion about how PrEP might fit within a youth’s goal for
healthy behaviors. In sessions 3 and 4, the CHW will review
the change plan, continue to elicit and reinforce change talk,
problem-solve barriers, consolidate commitment, and address
maintenance of behavior change.
Training of Interventionists
YMHP intervention training will occur before the initiation of
phase 2, with ongoing coaching and supervision and training
of new interventionists, as required. The interventionist training
team includes 2 members of the Motivational Interviewing
Network of Trainers from the CHEST, and this training
procedure includes (1) an initial 3-day training for CHWs and
local supervisors; (2) a 2- to 3-month training period of role-play
practice, coding and feedback, and supervision modeling,
including mock sessions with standardized participants role
played by CHEST research assistants; (3) 1-hour weekly
supervision sessions between local supervisors and CHWs; (4)
monthly supervision calls between local supervisors, the
interventionist training team, and the protocol lead including a
quarterly Skype booster training; and (5) ongoing quality
assurance and feedback using MITI coding.
All materials (eg, slides, training exercises, supervisory tools)
will be packaged for potential dissemination. Before
dissemination, any copyrighted media will be removed from
these materials. The initial 3-day training was held for all CHWs
and their supervisors in Miami and followed a curriculum
developed from previous NIH-funded effectiveness trials. CHWs
and supervisors participated together in days 1 and 2 of the
training. The third day of training was split so CHWs could
have more practice with the YMHP protocol and supervisors
could focus on coaching MI. CHEST provided external MITI
coding for the supervisors to use as feedback. Following the
3-day training workshop, all CHWs and supervisors submitted
audio recordings of all intervention sessions. Mock sessions are
completed as in-person and remote delivery with mock
participants. These sessions were MITI coded and CHEST
trainers provided coaching and feedback. Once beginner
competency was met, the local SRV supervisor took over weekly
individual supervision of the CHWs. Throughout YMHP, the
interventionist training team will continue to provide support
to supervisors for assistance in supervision and will focus on
having them practice listening for skills and then model for
them how to use MITI feedback.
Fidelity Monitoring
All sessions (clinic-based and remote-based) will be
audio-recorded, and one recording per CHW will be randomly
selected for MITI coding by the research team on a regular basis.
For the full trial, a random selection of 10% of the interviews
will be independently coded. Supervisors will complete fidelity
checklists for the supervision session so the team can monitor
implementation. The protocol lead and the interventionist
training team will facilitate quarterly boosters via group Skype
for supervisors. Before the quarterly boosters, supervisors will
submit a recording of a supervision session for review. Boosters
will cover successes and challenges, MITI scores, updated MI
skill development plans for each CHW, and role-plays of
supervision skills. The protocol lead and the interventionist
training team will join supervision sessions via Skype if MITI
scores fall below competency without remediation. They will
also lead annual in-person booster trainings covering MI skills
and specific delivery of YMHP for supervisors and CHWs. All
boosters will be recorded and qualitatively analyzed.
Results
Phase 1
Phase 1 was conducted in 2017, with site visits to Miami,
Detroit, and Philadelphia where focus groups were conducted
with youth. Focus groups participation breakdown is provided
in Table 1. The feedback from the focus groups at each clinic
has been used to modify the YMHP intervention before the
launch of phase 2. Phase 1 focus groups were conducted with
a total of 25 youth across the 3 SRVs to gather information that
would be used to better implement YMHP. Youth were divided
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into 2 age groups, 15 to 17 years and 18 to 24 years. The first
focus group was conducted in Detroit between June 7th and 9th
of 2017 with 14 scheduled potential participants. Out of those,
7 participants provided consent and participated in the group
discussion. The second focus group was conducted in
Philadelphia between July 10th and 11th with 23 scheduled
potential participants. Out of those, 8 participants provided
consent and participated in the group discussion. The final group
was conducted in Miami between July 12th and 14th with 20
scheduled potential participants. Out of those, 10 participants
provided consent and participated in the group discussion. A
total of 25 participants who reported their HIV status as negative
attended focus groups and provided their feedback on the YMHP
intervention.
Participants in focus groups were asked to provide feedback on
HIV testing and counseling experiences and how to incorporate
screening into the testing process, the YMHP intervention, and
barriers to completing participation in the study. Participants
reported positive experience working with the 3 sites and limited
negative experiences overall with testing and counseling. Many
participants expressed a lack of discussion about substance use
but a desire to engage in discussions about it with CHWs,
especially in the context of peer pressure from older partners.
Participants at all SRVs reported cocaine and ecstasy as
commonly used substances in their cities. When participants
were asked about the intervention, they expressed interest in
the remote delivery option. Many thought that the advantages
to sessions over the phone or video chat such as Skype and
FaceTime are that it eliminates transportation as a barrier to
session completion and the resistance of talking to a therapist
face-to-face. Participants also felt that individual characteristics
(eg, race, gender) of the CHW delivering the YMHP intervention
did not matter as long as they were confident with their
knowledge and the resources they are offering. In addition, they
perceived scheduling and discretion were the 2 biggest barriers
to completing sessions because of school and needing parents
to possibly transport them to and from appointments at the SRV,
while also having to explain the study to strict parents for youth
less than or equal to 18 years as an obstacle.
Table 1. Young Men’s Health Project focus groups.
ParticipantsDateSite





On the basis of the results from phase 1, for phase 2 we will
enroll 270 YMSM, with 90 participants per site and 135
participants in each of the 2 conditions. Recruitment for phase
2 began in October 2018, and all participant components are
projected to end in December 2020.
Intervention Outcomes and Measures
This study examines 4 coprimary outcomes related to substance
use (1 outcome) and sexual health management (3 outcomes).
These are measured during baseline; immediate postintervention;
and 3-, 6-, 9-, and 12-months follow-up assessments.
Specifically, sexual health management is measured by 3
outcomes: (1) decreased STIs, (2) decreased CAS, and (3)
increased PrEP uptake/adherence. HIV/STI testing occurs after
immediate postintervention at 3- and 9-month follow-up
assessments.
Substance use is measured using the Alcohol, Smoking and
Substance Involvement Screening Test (ASSIST) [60]. ASSIST
is often utilized as a screener in primary care settings for
substance abuse. Specifically, ASSIST assesses participants’
use of alcohol, tobacco, cannabis, sedative, hallucinogens,
inhalants, opioids, and other drugs. The primary substance use
outcome will be substance use days during the past 90 days.
To measure CAS, participants complete a series of questions
pertaining to their sexual behavior with main and casual partners
[61]. Participants estimate their total number of sex partners in
the past 3 months. Participants also indicate if they had
unprotected, receptive or insertive, anal sex with partners who
were HIV positive or of unknown HIV status.
The Motivational PrEP Cascade is a series of 21 questions that
are designed to assess PrEP treatment uptake and adherence
[62-64]. Participants report their familiarity with PrEP;
experiences and acceptability; as well as PrEP contemplation,
preparation, action, and maintenance utilizing the
Transtheoretical Model of Change framework. This includes
assessing willingness and intentions for PrEP uptake. The
Motivational PrEP Cascade also assesses when participants
begin and stop taking PrEP [65].
Putative Moderators and Mediators of Intervention
Effects
Moderators and mediators of intervention effects will be
assessed with health care access and other self-management
constructs for decision making, problem solving, self-regulation,
and provider and health care relationship. Health care access is
a series of 9 questions adapted from Williams and Chapman’s
unmet health and mental health need [66]. Items included
whether youth were not able to get health care services (ie,
routine physical examination, see a provider for sexual health
care or get access to PrEP, psychological or emotional
counseling, and counseling for drug or alcohol use) in the past
year when they felt they needed those services.
Self-management constructs included the Behavior Rating
Inventory of Executive Function (BRIEF-A) [67] and the Patient
Activation Measure [68]. BRIEF-A is a series of 22 questions
asking patients to rate whether certain problems (eg, bothered
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by having to deal with changes, do not plan ahead for tasks, and
problems completing my work) occurred in the past month.
Responses included never, sometimes, and often. For patient
activation measure, participants were asked on a 4-point scale,
ranging from strongly disagree to strongly agree or not
applicable, a series of 10 questions related to their health.
Examples of some of the questions include, “When all is said
and done, I am the person who is responsible for taking care of
my health” and “I am confident that I can follow through on
medical treatments I may need to do at home.”
Quantitative Analysis Plan
The primary hypothesis is that, although the main effect of
YMHP delivery modality will be nonsignificant, there will be
a significant interaction between access to health care and
delivery modality. Specifically, it is hypothesized that
remote-based YMHP will demonstrate greater improvements
in sexual health management (as measured by decreased STIs,
CAS, and increased PrEP uptake/adherence) as well as greater
reductions in substance use, compared with clinic-based YMHP,
among YMSM who do report barriers to health care access. In
contrast, it is hypothesized that clinic-based YMHP will
demonstrate greater improvements in sexual health management
and reduced substance use among YMSM who do not report
barriers to health care access.
The protocol lead and analytic team will test the effect of
clinic-based versus remote-based delivery on STI rates, alcohol
and drug use behavior, CAS, and PrEP uptake through multilevel
growth mixture modeling (GMM). A separate model will be
run for each outcome. Each model will be a 2-level model in
which individuals (level I) are nested in clinics (level II). This
approach controls for the nonindependence of individuals within
clinics. As 3 sites provide extremely limited predictive power
at level II, no site covariates are included in the model. The
models are empty at level II.
In a GMM, a latent growth curve with an intercept and linear
slope factor is specified. Latent class analysis is applied to these
2 growth components (intercept and slope) to identify groups
of individuals who share trajectories. For example, with regard
to drug or alcohol use, immediate and sustained responders
might have the lowest postintervention intercept and a flat slope.
Meanwhile, non-responders might have the highest
postintervention intercept and a flat slope. In contrast, delayed
responders might have a high postintervention intercept but a
significant negative slope, indicating reductions in missed
medication over the follow-up period.
If modeling results indicate that discrete classes are not present,
we will proceed with analyses in which the growth factors
(intercept and slope) are predicted directly by intervention
condition (and demographic factors found to be associated with
condition after randomization or with attrition over follow-up).
GMMs can subsequently incorporate predictors of class
membership. These analyses can be conceptualized as a
multinominal logistic regression with the latent trajectory-class
membership constituting the outcome. The predictors of primary
interest will be intervention condition, the presence of any
barriers to health care access, and the interaction between
condition and barriers to access. We will include as covariates
any demographic variables that were associated with condition
after randomization or with attrition over the follow-up period.
Power Analysis and Sample Size
Power analysis was conducted based on the 4 outcomes of STIs,
PrEP uptake, alcohol and drug use, and CAS. First, we analyzed
power assuming independence of participant observations
(assuming that the nesting of people within clinic was
irrelevant). With regard to STIs, we utilized the repeated
measures module of PASS 13.0 [NCSS Statistical Software] to
examine power to detect odds ratio differences in a repeated
measures design. Specifying compound symmetry, we allowed
ρ to vary between .2 and .5. Assuming the prevalence of STIs
in remote delivery condition varies between .05 and .15, the
proposed design (N=270) has power .80 to detect an odds ratio
of 0.20 to 0.50. Similarly, with regard to the odds of PrEP
uptake, allowing the rate of uptake in the remote delivery
condition to vary between .05 and .20 and allowing ρ to vary
between .4 and .7, the proposed design has power of .80 to detect
an odds ratio of 1.9 to 2.3. With regard to number of alcohol
and drug use days, we utilized the Tests for Two Poisson Means
module in PASS 13.0. On the basis of the data from our previous
studies, we allowed the rate of heavy drinking in the remote
delivery condition to vary between 7 and 9 days during a 30-day
assessment. The study is adequately powered to detect a 3%
reduction in the number of heavy drinking days in the in-person
condition at any single follow-up point. Allowing the rate of
substance use in the remote delivery condition to vary between
3 and 5 days during a 30-day assessment period, the study is
adequately powered to detect a 4% reduction in drug use in the
in-person condition. A similar analysis was conducted with
respect to CAS. On the basis of our previous research, we
allowed the rate of CAS in the remote delivery condition to vary
between 2 and 4 acts in a 30-day assessment period. The study
is powered to detect a difference as small as 5% between the
remote delivery and in-person YMHP conditions. The nesting
of individuals within sites has the potential to reduce power
because substantial variability in outcome across sites can
obscure level-II treatment effects [69,70]. The design effect can
be used to tailor power analyses calculated under assumptions
of independence. In the case of a level-I predictor with a fixed
effect that is uncorrelated with other covariates in the model,
the design effect is equal to the 1−ρ, where ρ is the intraclass
correlation or the percentage of variance accounted for by
variability between sites. In previous ATN intervention trials,
between clinic site variability in HIV-related outcomes did not
differ significantly from 0. We anticipate an absence of
variability across clinics, suggesting that the design effect would
result in a negligible reduction in power. Finally, a sample size
of 270 is sufficient to detect a moderation effect with an f2 of
0.02. Cohen [71] designates this as a small effect; however,
recent work has characterized an effect of this size as moderate
to large as applied to moderation [72].
Cost-Effectiveness
To enhance the likelihood of uptake if effective, the
cost-effectiveness of 2 delivery models of YMHP in reducing
sexual risk and substance use will be assessed utilizing CDC’s
guidelines for cost-effectiveness analysis on HIV infections
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averted. The economic analysis will have 2 components: (1) a
cost analysis of the YMHP intervention and (2) an incremental
cost-effectiveness analysis that compares the value of
clinic-delivery of YMHP over remote delivery. We will first
estimate the marginal costs of delivering the 2 formats of
YMHP. Using data from the modified Drug Abuse Treatment
Cost Analysis Program [73,74] and study contact and
expenditure records, key statistics from the cost evaluation will
include the total annual economic cost for each program, weekly
economic cost per client, and total economic cost per
intervention session [75-77]. To highlight the relative
contribution of the various cost components and necessary future
budgeting, we will also perform a descriptive analysis of the
cost accounted for by resource category.
The mean aggregate cost of the interventions will be used as
inputs in the cost-effectiveness model. Cost-effectiveness will
be modeled for clinic-delivery of YMHP as compared with
remote-delivery for the differences in CAS and predicted
through Markov modeling for 5 and 10 years and over a lifetime
using varying assumptions about decay of the effect of the
intervention over time. Modeling will be performed from the
perspectives of (1) a third-party payer, (2) the medical care
system, and (3) society.
Intervention Effects on Self-Management and Tests of
Putative Mediation
Using GMM models similar to those described above in primary
outcome analyses, we will examine the cross-time effects of
intervention on the 5 dimensions of self-management. Where
a significant between-condition difference in self-management
is detected, we will explore mediation by examining whether
intercept and/or growth factors for that dimension of
self-management in turn predict outcomes. Indirect effects in
GMM will be evaluated using bootstrapping estimation where
possible. When this is not possible, a constraint approach will
be employed. This approach involves comparing the fit of 2
models: one model in which the product of constituent pathways
is constrained to be 0 and another in which the product of the
direct effects is unconstrained. A significant Chi-square test
associated with this comparison indicates that the constraint
significantly diminishes model fit and constitutes evidence of
the significance of the indirect pathway [78].
Discussion
Principal Findings
The goals of this YMHP intervention are to better understand
HIV prevention–focused self-management behaviors among
HIV-negative YMSM and to study the implementation of YMHP
to improve portability and scalability. The SRVs will help to
assess and address practical problems at the frontline of service
provision to pave the way for a comprehensive program to
reduce HIV infection among YMSM that reflects the
complexities of real-world adolescent HIV clinics. If proven
successful, this intervention delivery could help YMSM across
the United States.
On the basis of previous studies, YMSM are at an even higher
risk for HIV and STIs than older MSM [3,23,25]. YMSM living
in urban areas and YMSM of color are especially at risk [6].
The need to lower these rates makes this study important.
Similar interventions have been effective in the past. In a study
of youth currently living with HIV, results showed that
participants who had attended MI sessions were more likely to
pursue behavior changes compared with participants in the
control condition. The more sessions a participant attended, the
better the results [5]. MI was also beneficial in a study of field
outreach for young black men for HIV counseling and testing.
The study found that outreach workers who had implemented
MI were more likely to encourage youth to learn about their
HIV status.
Implementing YMHP MI-based interventions targeting MSM
at risk has been shown to be effective in past studies. This study
is beneficial because it addresses the needs of the YMSM
population. In urban areas, access to care (information about
care or transportation means), PrEP information, and knowledge
of sexual health and substance use might not occur in schools
or with primary care providers; introducing all of this in a
specially tailored intervention will give youth the information
to lower their risk of HIV infection and STIs. It is important to
implement this strategy drawing on the success of YMHP
interventions in the past [79,80] because of the fact that YMSM
as the population continues to see a rise in new HIV infection
(132%), whereas rates among other groups have remained stable
[6].
To address concerns related to differential drop out in that more
remote delivery participants might never receive first session
and that it is quite possible that retention across the 4 sessions
is still higher in the remote condition because of transportation
issues for in-person delivery, everyone will be asked to complete
their session 1 in person regardless of their randomization to
the intervention conditions. This would also address concerns
some of the focus group youth had about developing a rapport
over the phone or video chat. We estimate that retention for the
IP and the 3-, 6-, 9-, and 12-month assessments will be 97%,
94%, 91%, 88%, and 85%, respectively, based on our previous
study on YMHP [80,81]. Through REDCap, each clinic site
will be able to generate reports for when YMSM are due for
follow-up assessments, and the lead site, CHEST Hunter
College, will provide extensive training to research assistants
on retention efforts.
In addition, as YMHP is being tested in conjunction with other
evidence-based practices in the Scale It Up program of research
[58], intervention applicability and affordability will be
determined through implementation science research methods
and cost-effectiveness analysis. These components will be
studied using EPIS to generate knowledge about the barriers
and facilitators to the implementation and sustainment of the
intervention into adolescent HIV prevention and clinical care
settings.
Limitations
This study has several possible limitations based on the
population and locations involved. Another limitation regarding
eligibility criteria is self-reporting of 3 or more days of substance
use and 1 episode of CAS in the past 90 days. However, with
the 3 SRVs HIV epicenters, intervention would be beneficial
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even as a preventative measure for this population. Although
this study has a waiver of parental consent, parents or guardians
might also come up as a barrier to participation. If parents do
not approve of participation, they might discourage potential
participants from participating or enrolled participants from
completing the full study by refusing to cooperate if
transportation to and from the clinic is dependent on the parent.
Transportation overall might limit which participants can make
it to appointments when they have to go to SRVs for testing,
such as in Detroit where the lack of efficient public
transportation is a barrier to participation in intervention studies.
This is one of the main reasons why remote-based delivery is
being tested in these real-world adolescent clinics.
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